89C8-ACE2

N/A

Report date: 2023/03/27 14:52:46

Base Information

Drug Name89C8-ACE2

Drug Alias Name89-C-8-ACE-289C8-ACE2

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionImmunostimulantsAnti-Coronavirus spike glycoproteinAngiotensin-converting enzyme 2 inhibitors

TargetsCoronavirus spike glycoproteinAngiotensin-converting enzyme 2

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator Companies +[1] N/A

China Registration ClassN/A

Develop Information

Active Companies +[1] N/A

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A